Citi: HUTCHMED (00013.HK) is approaching an inflection point in innovation, clinical trials, and sales recovery; reiterates "Buy" rating.

Citi released a research report stating that HUTCHMED (00013.HK) business operations have reached an inflection point driven by innovation, clinical progress, and sales recovery. The bank reiterated its "Buy/High Risk" rating with a target price of HK$40.1.